AL amyloidosis may respond to chemotherapy but two-thirds of patients with severe cardiac involvement die within a year of diagnosis, purportedly from tachyarrhythmias or electromechanical dissociation. We sought to characterize the nature of cardiac arrhythmias in severe cardiac AL amyloidosis using implanted cardiac rhythm recorders.
Introduction
The prognosis of systemic AL amyloidosis, in which misfolded monoclonal light chains are deposited in various tissues as insoluble amyloid fibrils, 1 is substantially influenced by the presence and severity of cardiac involvement. 2 The latter can be evaluated through serum biomarker concentration, 3 echocardiography and cardiac magnetic resonance imaging (CMR). 4 -6 One-third of patients with AL amyloidosis present with cardiac failure associated with marked elevation of both N-terminal pro-brain natriuretic peptide (NT-proBNP) and troponin T (TnT) concentration, 7 and are classified according to the widely used Mayo Clinic criteria to have Stage III poor prognosis disease. 3 Despite progress in chemotherapy, sudden cardiac death (SCD) occurs within 8 months in the majority of these patients, and only 29% survive a year. 7 -9 Whilst ventricular tachyarrhythmias and pulseless electrical activity (PEA) have been observed as terminal events, 10 -12 little is known about the electrical activity preceding terminal cardiac decompensation. There has long been interest in, but few systematic studies of, interventions including chemotherapy, anti-arrhythmic drug therapy, implantation of permanent pacemakers (PPM) or cardiac defibrillators (ICD) that might improve survival in cardiac AL amyloidosis. 13 Unfortunately, the very poor prognosis of patients with advanced Mayo Stage III cardiac AL amyloidosis 3, 7 has largely resulted in their exclusion from prospective clinical studies. 14 Furthermore, since consensus guidelines do not support ICD placement for primary prevention of SCD in patients with a life expectancy of ,1 year, 15 these devices have rarely been implanted in patients with cardiac AL amyloidosis. In one small cohort of patients with advanced symptomatic cardiac AL amyloidosis, ICD insertion did not appear effective in preventing SCD which was attributed to causes 'not amenable to ICD therapy'. 12 In contrast, two recent retrospective analyses of patients with cardiac amyloidosis identified ventricular tachyarrhythmias in a significant proportion of cases, some of which did respond to ICD therapy, 16 although this intervention was not associated with improved overall survival. 17 We sought to characterize the nature of, and disease-related risk factors for, cardiac arrhythmias in patients with severe cardiac AL amyloidosis by offering insertion of an implantable loop recorder (ILR) to a series of consecutive patients with newly diagnosed Mayo Stage III cardiac AL amyloidosis attending the UK National Amyloidosis Centre.
Methods Patients
Between July 2013 and May 2014, all patients attending the UK National Amyloidosis Centre with untreated, biopsy proven systemic AL amyloidosis who had an echocardiogram which was characteristic of cardiac infiltration by amyloid in conjunction with biomarkers indicating Mayo Stage III disease, and unexplained symptoms of either pre-syncope or syncope, were offered insertion of an ILR in accordance with National Institute of Health and Clinical Excellence (NICE) and European Society of Cardiology 18 guidance. None of the patients had previously received a cardiac device. All patients were treated in accordance with the Declaration of Helsinki and provided informed consent for insertion of the ILR and publication of data. Approval was obtained from the Royal Free Hospital Research Ethics Committee.
Baseline clinical assessments
A comprehensive clinical consultation was undertaken in each case. Further evaluation included an electrocardiogram (ECG), transthoracic echocardiogram including tissue Doppler imaging, whole body 123 I-serum amyloid P component scintigraphy (SAP scan), standardized 6 min walk test, lying and standing blood pressure measurements, New York Heart Association (NYHA) and Eastern Cooperative Group (ECOG) grading. Serological investigations included identification and quantitation of any circulating paraprotein and measurement of serum free light chains. First degree heart block and interventricular conduction delay were defined according to standard criteria. 19, 20 Diastolic dysfunction on echocardiography was graded as mild, moderate, or severe, 21 and left ventricular (LV) strain was determined by tissue Doppler imaging, as previously described.
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Patient treatment and follow-up
All patients received chemotherapy as standard treatment for systemic AL amyloidosis. All medications including details of each chemotherapy regimen and any changes in dosage were recorded at baseline and throughout the follow-up period.
Where relevant, time to death was recorded and every effort was made to obtain clinical details and ILR recordings of the terminal event. Where these showed a rhythm compatible with a cardiac output in the absence of such an output, the cause of death was attributed to pulseless electrical activity (PEA). Censor date for surviving patients was 1 October 2014.
Statistical analysis
All statistical analyses were carried out using the SPSS 16.0 statistical software package. Cox regression was used to determine factors at baseline associated with death. Hazard ratios and 95% confidence intervals were expressed per unit rise in each variable. Estimated median follow-up time was calculated by the reverse Kaplan-Meier method, and median patient survival was calculated by Kaplan-Meier analysis.
Results

Patients
Baseline characteristics of 20 consecutive patients with untreated, histologically proven systemic AL amyloidosis, and Mayo Stage III cardiac biomarkers are shown in Table 1 . Median serum highsensitivity TnT was 0.13 mg/L and median NT-proBNP concentration was 1410 pmol/L; 13 patients had NT-proBNP .1003 pmol/L (.8500 pg/mL), known to be associated with a particularly poor prognosis. 7 Organ involvement by amyloid, assessed by amyloid consensus criteria, 23 and by SAP scan within 1 day of ILR placement is shown in Table 1 . At baseline, six patients were receiving b-blocker therapy, one was receiving amiodarone and another took flecainide whenever he had symptomatic paroxysms of atrial fibrillation. Ten patients were receiving renin-angiotensin system (RAS) blockade and 17 were receiving loop diuretics (median daily furosemide dose equivalent 40 mg) of whom two were additionally receiving 50 mg daily of spironolactone. Eighteen patients, including one who was known to have paroxysmal atrial fibrillation, were in sinus rhythm (SR), one was in atrial flutter with variable AV block, and one had atrial fibrillation. The PR interval was normal at baseline among 8 of 18 patients, first degree heart block was present in 9 of 18 cases, and one patient had Mobitz type 1 second degree AV block (Wenckebach phenomenon). There was intraventricular conduction delay in 11 of 20 patients, Estimated median follow-up time from ILR placement was 308 days (range 10-399). All patients received chemotherapy as treatment for their systemic AL amyloidosis, commenced a median of 16 days after insertion of the ILR. Most received cyclophosphamide, bortezomib (Velcade), and dexamethasone (CVD) chemotherapy and the bortezomib and cyclophosphamide in each case were administered once per week at doses of 0.7 -1.0 mg/m 2 and 250-500 mg respectively; steroid regimens and doses varied substantially ( Table 2) .
Patient deaths
Thirteen patients died and median overall survival was 61 days.
Weekly ILR recordings in all 13 patients failed to identify potentially fatal dysrhythmias during the course of treatment other than the immediate pre-cardiac arrest rhythm, identified only when the ILR was obtained posthumously ( Table 3) . Eight of 13 patients died in hospital and the terminal event in all eight cases was PEA. Median time from onset of dysrhythmia to PEA was 1 h (range 0.1 -48 h). Five patients died at home or in a hospice. The immediate pre-cardiac arrest recordings were retrieved from 8 of 13 patients and in all cases the initial change in cardiac rhythm was bradycardia ≤35 bpm ( Table 3 , Figure 1A ), including complete atrioventricular block (CAVB) in six cases. Only one episode of rapid VT was recorded and this arose during CAVB-associated extreme bradycardia and spontaneously reverted to CAVB after 60 s ( Figure 1B) . Table 1) .
Arrhythmias
A total of 272 downloads were received during the course of the study. Interestingly, none of the symptom-driven manual downloads showed any rhythm change from baseline. Arrhythmias that were captured automatically by the ILR and medical interventions for those arrhythmias are shown in Table 2 . Six (30%) patients had atrial arrhythmias detected at some point during the study period, including four patients who were in SR at baseline but developed an atrial arrhythmia during the course of follow-up. One of six such patients was rate controlled without a requirement for antiarrhythmic medication, three cases were successfully rate controlled with amiodarone, one with a b-blocker, and one patient underwent successful atrial flutter ablation. One patient who was alive at censor and had first degree heart block at baseline, developed 2 : 1 AV block which rapidly progressed to CAVB prior to receiving chemotherapy. He was not receiving anti-arrhythmic therapy. He maintained his blood pressure until he had a pacemaker implanted on which he remained dependent throughout six cycles of CVD chemotherapy and at censor, 300 days later.
Timing and dosage of chemotherapy in relation to onset of change in cardiac rhythm, including pre-terminal bradyarrhythmias, was variable and there was no consistent pattern to suggest that any particular chemotherapeutic agent or dosage was pro-arrhythmogenic. Among a total of nine patients who developed severe bradycardia during the study, four were receiving b-blocker therapy and one was receiving amiodarone at the time. One of seven surviving patients was receiving b-blocker therapy at censor, bisoprolol 1.25 mg daily.
Discussion
This is the first study of ILR placement in a series of patients with cardiac AL amyloidosis. Mayo Stage III cardiac AL amyloidosis is associated with a high rate of SCD, particularly in patients with a history of syncope, and this study confirms previous observations. 13, 24 However, the surprising and completely novel finding here was that every available recording from the terminal syncopal phase prior to death showed that the initial cardiac decompensation was associated with development of marked bradycardia, usually caused by CAVB, and that despite chemotherapy with CVD, there was only one episode of non-sustained ventricular tachycardia observed throughout the whole follow-up period. Our findings are consistent with previous suggestions that the terminal event in patients with cardiac AL amyloidosis is typically EMD/PEA, 25 and also supports those who have reported that ventricular arrhythmias are uncommon in cardiac AL amyloidosis, 12, 13 although the data in this regard are conflicting. 10, 17 The reasons for these discrepancies remain unclear but might be related to use of different heart failure or chemotherapeutic agents or alternatively, related to disease severity. It is possible that ventricular tachyarrhythmias in cardiac amyloidosis are frequently self-limiting and tend to occur in patients with relatively early stage disease but that, as the disease progresses, the likelihood of AV block and consequent bradycardia increases. This hypothesis would also be consistent with the fact that ventricular tachyarrhythmias have been reported to be amenable to ICD therapy and have not generally been found to be an independent risk factor for poor prognosis in the context of AL amyloidosis. 16 We propose two hypotheses regarding the pathogenic significance of severe bradycardia in cardiac AL amyloidosis. It might simply be a pre-terminal event which reflects an irreversibly sick amyloidotic myocardium which cannot be salvaged by intervention. Alternatively, however, the reduction of cardiac output associated with bradycardia might be sufficient to induce global ischaemic stunning of the heavily infiltrated ventricular myocardium which, unless the ischaemic insult is rapidly reversed, triggers progressive decompensation resulting in PEA within a short period. This latter explanation is reminiscent of the observation that acute tubular necrosis, which is usually a reversible renal lesion which complicates an episode of renal ischaemia, rarely recovers in the context of preexisting renal amyloidosis however minor the ischaemic insult. 26 If ischaemic stunning is indeed the mechanism, it is likely that there may only be a very narrow time window in which to intervene among patients with cardiac AL amyloidosis who develop bradycardia. In keeping with this hypothesis, the only patient in the cohort who survived severe bradycardia had his PPM inserted before losing cardiac output, whereas three patients who received a pacemaker after resuscitation from PEA succumbed shortly thereafter. These two hypotheses could be reliably distinguished by prophylactic pacemaker insertion into patients with amyloidosis who have pre-syncope or syncope. Given the procedural risk associated with pacemaker insertion, coupled with the small sample size presented here, routine insertion of pacemakers into this patient population cannot yet be recommended. However, we believe that an ethically approved study of prophylactic pacemaker insertion into a cohort of patients with the clinical features described here would now be appropriate. If interrogation of the pacemakers revealed that rapid correction of bradycardia by cardiac pacing failed to prevent death, this would constitute strong evidence that bradycardias are a 'symptom' rather than a 'cause' of terminal amyloidotic myocardial failure. Interestingly, a recent study of prophylactic pacemaker insertion among patients with familial amyloid polyneuropathy, who typically have cardiac and neuropathic infiltration by amyloid composed of variant transthyretin and are at risk of conduction disorders, showed a reduction in major cardiac events over a 45-month mean follow-up among those who received pacemakers. 27 It is noteworthy that the absence of a definite survival advantage conferred by ICD implantation in individuals with cardiac AL amyloidosis 12, 17 does not exclude potential benefit from permanent pacemaker insertion and is entirely in keeping with our findings; the manufacturer's setting for the pacing capability of standard ICD devices is routinely 35 bpm, similar to the typical ventricular escape rate among patients with CAVB, and it may simply be that the reduction in cardiac output associated with this cardiac contraction rate in an individual with a small, stiff ventricle exhibiting restrictive physiology is sufficient to induce global myocardial 'stunning' thus triggering the irreversible decline highlighted above. One important remaining question is whether chemotherapeutic agents that are administered to treat systemic AL amyloidosis may worsen prognosis among those with severe cardiac infiltration, either by promoting arrhythmias or affecting systolic function. Among this small group of severely affected individuals, nearly all of whom received combination chemotherapy with cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD), there was no indication of direct drug toxicity; arrhythmias/SCD did not occur within 48 h of administration of chemotherapy in any patient in the series. Furthermore, one patient developed CAVB prior to receiving chemotherapy, indicating a substantial contribution to the conduction disturbance from the disease itself. Similarly, whether b-blocker therapy should be completely avoided in patients with cardiac AL amyloidosis is not known and needs to be prospectively evaluated. The main limitation of this study is the small sample size. It should also be noted that only patients with very poor prognosis disease were included; whether the findings are applicable to patients with less severe cardiac AL amyloidosis remains unknown and should be the subject of further ILR studies.
In conclusion, this study of ILR placement in a cohort of patients with advanced, poor prognosis cardiac AL amyloidosis, the first of its kind in this disease, showed that onset of severe bradycardia heralded the terminal decline in every evaluable patient who died. Further ILR studies in patients with cardiac AL amyloidosis, including those with less advanced disease, and those receiving a wide variety of chemotherapeutic agents as well as conventional anti-arrhythmic and cardiac failure medications, will be useful to definitively determine the cause, frequency and nature of cardiac arrhythmias in this patient population. A clinical study of pacemaker insertion into patients with advanced, poor prognosis cardiac AL amyloidosis is now warranted.
